Skip to search formSkip to main contentSkip to account menu

TRU 016

Known as: TRU-016 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Immunoglobulin GRecombinant Fusion Proteins

Narrower (1)

otlertuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
Review
2014
Review
2014
Anti-CD37 antibodies for chronic lymphocytic leukemia
Introduction: Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and… 
2013
2013
Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
2012
2012
Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej
2012
2012
Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia
Abstract 1795 Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide… 
2011
2011
Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients
Abstract 1792 Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide… 
2010
2010
Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL
Abstract 56 Background: CD37 is a member of the tetraspanin superfamily of molecules which are implicated in diverse processes… 
2010
2010
TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma
Abstract 3931 Background: CD37 is a 50–55 kDa heavily glycosylated member of the tetraspanin superfamily of molecules. This cell… 
2009
2009
Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent… 
2009
2009
A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.
Abstract 3424 Poster Board III-312 Background CD37 is a tetraspanin family member expressed predominantly on normal and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)